[en] Crohn's disease (CD) is a multifactorial disease with genetic heterogeneity. TNF-alpha plays a key role in the development of the mucosal lesions. The aim of our work was to study a single base pair polymorphism located in the promoter region of TNF gene, in a large population of CD patients with well defined phenotypes. One hundred and ninety-three patients with CD and 98 ethnically matched controls were studied. The -308 single base pair polymorphism of TNF gene was studied using an allele-specific polymerase chain reaction. Genotype and allelic frequencies were compared between patients and controls and between subgroups of patients defined by sex, age at diagnosis, familial history, location of disease, type of disease, extra-intestinal manifestations, and response to steroid treatment. In 29 patients a measure of TNF-alpha production by colonic biopsies was performed. The frequency of the allele TNF2 as well as the proportion of carriers of the allele TNF2 were slightly but not significantly lower in CD than in controls (11.9% versus 14.8% and 21.5% versus 27.6%, respectively). A more prominent difference in frequencies of allele TNF2 and in proportions of TNF2 carriers was found when comparing subgroups of patients. The frequency of allele TNF2 was significantly higher in steroid-dependent than in non-steroid-dependent disease (28.1% versus 10.3%; Delta = 17.8%, 95% confidence interval (CI) = 6.3-29.5%, P = 0.0027) and tended to be higher in colonic than in small bowel disease and in fistulizing than in stricturing disease. Furthermore, TNF2 carriers tended to be more frequent in patients with steroid-dependent than non-steroid-dependent disease (43.8% versus 19.3%; Delta = 24.5%, 95% CI = 3.6-45.4%, P = 0.022), in patients with fistulizing than stricturing disease (26.5% versus 9.6%; Delta = 16.9%, 95% CI = 1. 1-32.6%, P = 0.036), and in patients with colonic than small bowel disease (26.5% versus 11.1%; Delta = 15.4%, 95% CI = -0.8-31.6%, P = 0.063). Finally, patients carrying at least one copy of allele 2 were found to produce slightly more TNF-alpha at the colonic level. The -308 TNF gene polymorphism may have a slight influence on the behaviour of CD. The carriage of allele 2 may favour steroid-dependent disease and to a lesser extent fistulizing and colonic disease, possibly secondary to a more intense TNF-alpha-driven inflammatory reaction at the mucosal level.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Peeters, Marc
Franchimont, D.
Seidel, Laurence ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique
Fontaine, Fernand
Demolin, G.
Croes, F.
Dupont, P.
Davin, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
Omri, S.
Rutgeerts, P.
Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
Tumour Necrosis Factor (Tnf) Gene Polymorphism in Crohn's Disease (Cd): Influence on Disease Behaviour?
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
1 Satsangi J, Jewell DP, Rosenberg WMC, Bell JI. Genetics of inflammatory bowel disease. Gut 1994; 35:696-700.
2 Tysk C, Lindberg E, Järnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988; 28:990-6.
3 Hugot JP, Laurent-Puig P, Gower-Rousseau C et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379:821-3.
4 Satsangi J, Parkes M, Louis E et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nature Genetics 1996; 14:199-202.
5 Peeters M, Nevens H, Baert F, Hiele M, De Meyer AM, Vlietinck R, Rutgeerts P. Familial aggregation in Crohn's disease: increased aged-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996; 111:597-603.
6 Colombel JF, Grandbastien B, Gower-Rousseau C et al. Clinical charateristics of Crohn's disease in 72 families. Gastroenterology 1996; 111:604-7.
7 Bouma G, Poen AC, Garcia-Gonzalez MA, Schreuder GMT, Felt-Bersma RJF, Meuwissen SGM, Pena AS. HLA-DRBI *03, but not the TNFA-308 promoter gene polymorphism, confers protection against fistulising Crohn's disease. Immunogenetics 1998; 47:451-5.
8 Plevy SE, Taylor K, De Woody KL, Schaible TF, Shealy D, Targan SR. Tumor necrosis factor (TNF) microsatellite haplotypes and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) identify Crohn's disease (CD) patients with poor clinical response to anti-TNF monoclonal antibody (cA2). Gastroenterology 1997; 112:A1062.
9 Heresbach D, Alizadeh M, Bretagne JF et al. TAP gene transporter polymorphism in inflammatory bowel diseases. Scand J Gastroenterol 1997; 32:1022-7.
10 Dionne S, Hiscott J, D'Agata I, Duhaime A, Seidman EG. Quantitative PCR analysis of TNF-α and IL-1β mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 1997; 42:1557-66.
11 Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP. Enhanced secretion of tumor necrosis factor-alpha, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94:174-81.
12 Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997; 349:521-4.
13 Targan SR, Hanauer SB, Van Deventer SJH et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337:1029-35.
14 Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG, Holdsworth CD, Duff GW. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106:637-42.
15 Bouma G, Xia B, Crusius JBA, Bioque G, Koutroubakis I, Von Blomberg VME, Meuwissen SGM, Pena AS. Distribution of four polymorphisms in the tumor necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996; 103:391-6.
16 Louis E, Satsangi J, Roussomoustakaki M, Parkes M, Fanning G, Welsh K, Jewell DP. Cytokine gene polymorphisms in inflammatory bowel disease. Gut 1996; 39:705-10.
17 Plevy SE, Targan SR, Yang H, Fernandez D, Rotter JI, Toyoda H. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology 1996; 110: 1053-60.
18 Heresbach D, Ababou A, Bourienne A et al. Tumor necrosis factor gene and microsatellite polymorphism in chronic inflammatory bowel diseases. Gastroenterol Clin Biol 1997; 21:555-61.
19 Wilson AG, Symons JA, McDowel TL, McDevitt HO, Duff GW. Effect of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94:3195-9.
20 Bouma G, Crusius JBA, Oudkerk Pool M et al. Secretion of tumor necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996; 43:456-63.
21 Louis E, Franchimont D, Piron A et al. Tumor necrosis factor gene polymorphism influences tumor necrosis factor α production in LPS-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113:401-6.
22 Bunce M, Taylor CJ, Welsh KI. Rapid HLA-DQB typing by eight PCR amplifications with sequence-specific primers (PCR-SSP). Human Immunol 1993; 37:201-6.
23 Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B. Increased production of tumor necrosis factor-α, interleukin-1β and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39:684-9.
24 Wardle TD, Hall L, Turnberg LA. Use of coculture of colonic mucosal biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease. Gut 1992; 33:1644-51.
25 Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32:174-8.
26 Sher ER, Leung DYM, Surs W, Kam JC, Zieg G, Kamada AK, Harbeck R, Szefler SJ. Steroid resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93:33-9.
27 Van der Burg B, Liden J, Okret S, Delaunay F, Wissink S, Van der Saag PT, Gustafsson JA. Nuclear factor-κB repression in anti-inflammation and immunosuppression by glucocorticoids. Trends Endocrinol Metab 1997; 8:152-7.
28 McGuire W, Hill AVS, Allsopp CEM, Greenwood BM, Kiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371:508-11.
29 Conway DJ, Holand MJ, Bailey RL, Campbell AE, Mahdi OMS, Jennings R, Mibena E, Mabey DCW. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-α) gene promoter and with elevated TNF-α levels in tear fluid. Infect Immun 1997; 65:1003-6.
30 Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) - 308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 1995; 46:32-41.
31 Westendorp RGJ, Langermans JAM, Huizinga TWJ, Elouali AH, Verwij CL, Boomsma DI, Vandenbroucke JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349:170-3.
32 Wilson AG, De Vries N, Pociot F, Di Giovine FS, Van der Putte LBA, Duff GW. An allelic polymorphism within the human tumor necrosis factor α promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177:557-60.
33 Roy S, McGuire W, Mascie-Taylor CGN, Saha B, Hazra SK, Hill AVS, Kiatkowski D. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis 1997; 176:530-2.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.